Founded in September 2016, Uniceutiq focuses on the development of suspension drugs for pediatric use and is the only company in China that dedicated in the development of such drugs.

Founded in 2003, Mitralign is the only company in the world that has commercial devices for both mitral and tricuspid minimally invasive repairment. It is the minimally invasive valve device company with the largest patient number, longest follow-up, best outcomes, and fastest progress in clinical trials for tricuspid minimally-invasive devices. 

Recida  focused on developing first-in-class anti-infective medicines for the treatment of multi-drug resistant infections. The company is currently advancing its novel LpxC inhibitor, RC-01.